Navigation Links
Actavis Launches Carvedilol Tablets in the U.S.
Date:9/5/2007

MORRISTOWN, N.J., Sept. 5 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Carvedilol tablets in the U.S.. Distribution of the product will commence immediately.

Carvedilol tablets, the generic equivalent of GlaxoSmithKline's Coreg(R) tablets, will be available in 3.125, 6.25, 12.5 and 25 mg strength. Carvedilol tablets are indicated for the treatment of left ventricular dysfunction following myocardial infarction and for the management of essential hypertension.

Annual sales of carvedilol tablets in the U.S. were approximately US$1.7 billion for the twelve months ending June 2007 according to IMS Health data.

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 39 countries, with 11,000 employees. Actavis expects 2007 sales to total EUR1.6bn, with approximately one-third of these sales coming from the United States, the company's single largest market. In the U.S. alone, the company made 38 ANDA filings in 2006 and expects to file 40-45 in the year 2007 along with 18-20 new product launches. The company's U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at http://www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environ


'/>"/>
SOURCE Actavis Group
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Glaxo launches pills to help smokers quit in 7-12 weeks
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. Dr Reddy’s Laboratories launches Hyalosy
4. Serum Institute Launches New Tetanus-Diphtheria Vaccine
5. Scottish Health Minister Launches Organ Donor Plan
6. GlaxoSmithKline launches diabetes and cancer drugs
7. Pfizer Launches Viagra For Lung Disease In UK
8. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
9. PM Launches Healthcare Foundation For India
10. African Union Launches A Programme On Acceleration of HIV Prevention
11. Yale School of Medicine Launches Telemonitoring Of Heart Failure Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , ... February 28, 2017 , ... ... premiere organization in North America for the scientific development, healthcare training and clinical ... Annual Meeting & Scientific Session on September 16-17 in Greenville, SC at the ...
(Date:2/28/2017)... Lake City, Utah (PRWEB) , ... February 28, 2017 , ... ... Month is a time for everyone to reaffirm their commitment to improving cardiovascular health ... cause of death for men and women. Every year, one in four deaths are ...
(Date:2/28/2017)... ... February 28, 2017 , ... Roxanna ... 4:30-5:30 p.m. at the 11th Annual RISE Nashville Summit. RISE Nashville is the ... analytics, and engagement strategies. , The discussion will include best practices for accurate ...
(Date:2/27/2017)... ... ... Robert E. Burke, MD, PhD, had a successful career as a pediatrician and ... have led him down a much different path. , In his book, “Beyond the ... Dr. Burke shares a personal account of the tribulations he encountered on his path ...
(Date:2/27/2017)... ... 2017 , ... Elisa Guajardo Carothers is not your typical author. She went from working as ... Now, she writes about God, when she isn’t swimming as a performing mermaid. , Her ... BS! (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, before ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017  A landmark study led ... MBBS, PhD, FRACS, of  Sydney Heart and Lung ... will be published in the February 28, 2017 issue ... College of Cardiology . According to the study, which involved 37,720 ... surgery technique (anOPCABG) reduced postoperative stroke by ...
(Date:2/27/2017)... TAMPA, Fla. , Feb. 27, ... medical device company focused on developing cerebral embolic ... the members of the FDA,s Circulatory System Devices ... acknowledgement of the need for cerebral protection following ... "The statements shared by this FDA panel support ...
(Date:2/27/2017)... -- Now in its seventh year, the Pharmaceutical ... successful at developing and commercialising innovation. ... The Index can be summarised ... two different companies in early phase, which would make the ... of each company,s performance between 2011 and 2016, the 2017 ranking sees ...
Breaking Medicine Technology: